Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
CMSC
-0.0900
The Fort Worth Press - Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
USD
-
AED 3.67315
AFN 62.999676
ALL 83.250102
AMD 377.360416
ANG 1.790083
AOA 917.000211
ARS 1368.119097
AUD 1.450647
AWG 1.8025
AZN 1.701658
BAM 1.695925
BBD 2.012738
BDT 122.6148
BGN 1.709309
BHD 0.377021
BIF 2970
BMD 1
BND 1.284247
BOB 6.920712
BRL 5.239503
BSD 0.999302
BTN 94.168452
BWP 13.739161
BYN 3.001028
BYR 19600
BZD 2.009859
CAD 1.38635
CDF 2285.499459
CHF 0.794503
CLF 0.02346
CLP 926.340188
CNY 6.91145
CNH 6.919885
COP 3690.23
CRC 463.31745
CUC 1
CUP 26.5
CVE 95.875006
CZK 21.253202
DJF 177.720036
DKK 6.479603
DOP 59.502553
DZD 133.033338
EGP 52.693302
ERN 15
ETB 157.149735
EUR 0.867165
FJD 2.257398
FKP 0.747836
GBP 0.75005
GEL 2.69501
GGP 0.747836
GHS 10.959729
GIP 0.747836
GMD 73.506691
GNF 8777.501607
GTQ 7.644781
GYD 209.069506
HKD 7.82675
HNL 26.520299
HRK 6.534598
HTG 130.870053
HUF 336.598088
IDR 16920.45
ILS 3.124103
IMP 0.747836
INR 94.37435
IQD 1310
IRR 1313300.000273
ISK 124.359811
JEP 0.747836
JMD 157.053853
JOD 0.708982
JPY 159.709065
KES 129.891784
KGS 87.449964
KHR 4015.000285
KMF 427.000096
KPW 900.057798
KRW 1513.692106
KWD 0.30721
KYD 0.832809
KZT 481.430095
LAK 21737.520072
LBP 89574.002708
LKR 314.289307
LRD 183.701488
LSL 17.049774
LTL 2.95274
LVL 0.60489
LYD 6.379787
MAD 9.34039
MDL 17.552896
MGA 4175.000212
MKD 53.444613
MMK 2099.983779
MNT 3583.827699
MOP 8.05281
MRU 40.110111
MUR 46.620189
MVR 15.460253
MWK 1736.000329
MXN 17.947006
MYR 3.994042
MZN 63.910237
NAD 17.049902
NGN 1385.45992
NIO 36.719729
NOK 9.693796
NPR 150.669869
NZD 1.736335
OMR 0.384542
PAB 0.999298
PEN 3.459502
PGK 4.309495
PHP 60.069581
PKR 279.250135
PLN 3.70965
PYG 6540.378863
QAR 3.656497
RON 4.420698
RSD 101.821
RUB 81.371743
RWF 1460
SAR 3.751734
SBD 8.041975
SCR 13.873228
SDG 601.000258
SEK 9.42361
SGD 1.285397
SHP 0.750259
SLE 24.550215
SLL 20969.510825
SOS 571.502199
SRD 37.562015
STD 20697.981008
STN 21.35
SVC 8.74425
SYP 111.44287
SZL 17.050355
THB 32.889745
TJS 9.563521
TMT 3.51
TND 2.923497
TOP 2.40776
TRY 44.372597
TTD 6.782836
TWD 31.945003
TZS 2575.000218
UAH 43.849933
UGX 3717.449554
UYU 40.512476
UZS 12190.000172
VES 466.018145
VND 26351
VUV 119.023334
WST 2.74953
XAF 568.80967
XAG 0.014678
XAU 0.000228
XCD 2.70255
XCG 1.80106
XDR 0.705441
XOF 566.496279
XPF 103.703721
YER 238.649917
ZAR 17.119098
ZMK 9001.176996
ZMW 18.762411
ZWL 321.999592
- Czechs fight back to beat Ireland in World Cup play-off
- Wales' World Cup dream ended by Bosnia and Herzegovina
- Mbappe on target as France shrug off red card to beat Brazil
- Italy beat Northern Ireland to keep World Cup hopes alive
- Mexico blames oil slick on illegal dumping
- Gyokeres treble sends Sweden past Ukraine in World Cup play-offs
- OpenAI shelves plans for erotic chatbot
- Malinin soars above rivals at worlds as Germans win pairs gold
- Klopp hails Salah as one of Liverpool's 'all-time greats'
- Sinner and Gauff advance with ease at Miami Open
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
BOCA RATON, FL / ACCESS Newswire / November 28, 2025 / Entero Therapeutics, Inc. (NASDAQ:ENTO) (the "Company") today announced that it will change its name to GridAI Technologies Corp., effective at 12:01 Eastern Time on Monday, December 1, 2025. The name change closely aligns the Company's business following its acquisition of 100% of GRID AI Corp ("GRID AI"), a grid-edge, AI-driven software and controls platform that enables utilities, retail energy providers, and large power users to dynamically manage load and distributed energy resources including battery energy storage systems. In connection with the name change, the Company will change its ticker symbol to "GRDX". The Company's common stock will commence trading on the Nasdaq Capital Market exchange under the new name and trading symbol on December 1, 2025.
"This marks the beginning of a new chapter for the business," said Jason Sawyer, Interim Chief Executive Officer of GridAI Technologies Corp. "Our mission is to enhance grid-edge intelligence using AI, machine learning and edge analytics by orchestrating supply and demand in real time, creating a more reliable, resilient, and transactive grid -now supported with our public-company platform - and this name change reflects that commitment."
The name and future ticker change do not affect the Company's legal structure, business operations, or existing financial reporting obligations. Shareholders are not required to take any action in connection with the change.
Further updates will be provided via regular press releases and regulatory filings.
About Entero Therapeutics, Inc. (NASDAQ:ENTO)
Entero Therapeutics, Inc. is a publicly listed company on Nasdaq. The Company is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The Company's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency. Following completion of the GRID AI acquisition, the Company intends to continue these prior operations and to also operate GRID AI as a wholly owned subsidiary and pursue opportunities at the intersection of AI and energy infrastructure.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding strategic benefits of the acquisition, market opportunities, product capabilities, stockholder approval of the transaction, Nasdaq's approval of an initial listing application, if any, and future operating results. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. Important factors include, among others, our business strategy; the risk that regulatory or third-party approvals are delayed or not obtained; integration challenges; market adoption; competitive dynamics; macroeconomic and energy-market conditions; and other risks detailed from time to time in the Company's SEC filings. The Company undertakes no obligation to update forward-looking statements.
Investor & Media Contacts:
Entero Investor Relations
[email protected]
SOURCE: Entero Therapeutics, Inc.
View the original press release on ACCESS Newswire
H.M.Hernandez--TFWP
